首页> 美国卫生研究院文献>Springer Open Choice >Injectable Poly-l-Lactic Acid: A Novel Sculpting Agent for the Treatment of Dermal Fat Atrophy After Severe Acne
【2h】

Injectable Poly-l-Lactic Acid: A Novel Sculpting Agent for the Treatment of Dermal Fat Atrophy After Severe Acne

机译:注射用聚乳酸:一种新型雕刻剂用于治疗严重痤疮后的皮肤脂肪萎缩

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acne vulgaris affects up to 80% of people 11 to 30 years of age, and scarring can occur for up to 95% of these patients. Scarring may be pitted or hypertrophic in nature, although in most cases it is atrophic. Atrophic acne scarring follows dermal collagen and fat loss after moderate to severe acne infection. Injectable poly-L-acid (PLLA) is a biocompatible, biodegradable, synthetic polymer device that is hypothesized to enhance dermal volume via the endogenous production of fibroblasts and, subsequently, collagen. The gradual improvements in cutaneous volume observed after treatment with injectable PLLA have been noted to last up to 2 years. The case studies presented describe the use of injectable PLLA to correct dermal fat loss in macular atrophic acne scarring of the cheeks. Two female patients underwent three treatment sessions with injectable PLLA over a 12-week period. At each treatment session, the reconstituted product was injected into the deep dermis under the depressed portion of the scar. Both patients were extremely pleased with their results at, respectively, 1- and 4-year follow-up evaluations. Patients experienced minimal swelling and redness after injection and no product-related adverse events such as papule and/or nodule formation. The author believes these data suggest that injectable PLLA is a good treatment option for the correction of macular atropic scarring with thin dermis (off-label use), particularly compared with other injectable fillers currently used for this indication that have shorter durations of effect.
机译:寻常痤疮会影响11至30岁年龄段的人群中的80%,其中95%的患者会出现疤痕。疤痕在本质上可能是点蚀或肥大的,尽管在大多数情况下是萎缩的。在中度至重度痤疮感染后,萎缩性痤疮疤痕继之以真皮胶原蛋白和脂肪损失。可注射的聚L-酸(PLLA)是一种生物相容性,可生物降解的合成聚合物设备,据推测可通过内源性生成成纤维细胞和随后的胶原蛋白来增加皮肤体积。注射PLLA治疗后观察到的皮肤容量逐渐改善已持续了2年。提出的案例研究描述了使用可注射的PLLA纠正脸颊黄斑萎缩性痤疮疤痕中皮肤脂肪的减少。两名女性患者在12周的时间内接受了3次注射PLLA的治疗。在每个治疗阶段,将重组产品注射到疤痕凹陷部分下方的深层真皮中。两名患者分别在1年和4年的随访评估中对结果感到非常满意。注射后患者出现最小的肿胀和发红,并且没有产品相关的不良事件,如丘疹和/或结节形成。作者认为,这些数据表明,可注射的PLLA是矫正具有较薄真皮层的黄斑萎缩性瘢痕(标签外使用)的良好治疗选择,特别是与目前用于该适应症的其他可注射填充剂相比,其作用时间更短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号